Find out if gene therapy has also find its way into skin diseases. With two approvals in the last 2 years, is it the start of ...

22."A friend's brother-in-law was dying of cancer when, near the end, he got very excited and said, 'He's here! He's here! He ...

The gene editor -- called evoCAST -- goes a long way toward solving a problem that has confounded the development of gene therapies from the field's beginnings: How to add long stretches of DNA to ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.

Hemostasis Testing Systems Market projected to grow significantly from 2025 to 2035, driven by rising demand for advanced ...

Takeda is organized around five core businesses: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for over 80% of revenue. It also has a developing ...

The Daedric artifacts are some of the most powerful objects in the Elder Scrolls lore - here's how they stack up in Oblivion ...

Jivi antihemophilic factor is now approved for children aged 7-12 with hemophilia A, expanding its previous approval for older patients. Hemophilia A is more common than hemophilia B, with early ...

to include previously treated pediatric patients aged 7 years and older with hemophilia A (congenital Factor VIII deficiency), in addition to adults. For on-demand treatment and control of ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

BIOVF shifts to a strategic portfolio emphasizing Haematology, driving strong revenue growth. Key catalysts in 2025.